328918-88-3

Upstream product

• 42806-90-6 2-(4-hydroxyphenoxy)-2-methyl propionic acid ethyl ester 
• 328918-86-1 toluene-4-sulfonic acid 2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethyl ester 
• 328918-85-0 2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethanol 
• 328918-82-7 2-(4-bromophenyl)-5-methyl-4-oxazoleacetic acid 
• 328918-84-9 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol 
• 328918-83-8 [2-(4-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 
• 328918-81-6 2-(4-bromophenyl)-4-(chloromethyl)-5-methyl-1,3-oxazole 
• 328918-80-5 4,5-dimethyl-2-(4-bromophenyl)-oxazole oxide 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 328918-26-9 2-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid 

Relevant academic research and scientific papers

Modulators of peroxisome proliferator activated receptors

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented b

Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: A new class of dual PPARα/γ agonists

Propionic acid derivative 8, which was designed and synthesized based on putative pharmacophores of known PPARγ- and PPARα-selective compounds, exhibits potent dual PPARα/γ agonist activity as demonstrated by in vitro binding and dose overlap in the newly